Karl Ægir Karlsson

Karl Ægir Karlsson

Auto-generated profile, based on publicly available information

Karl Ægir Karlsson

Department of engineering, Reykjavik University, Iceland

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 September 2006 in Hippocampus
Verified
Journal Article
Closed access
PDF file
KKKarl Æ. Karlsson
Karl Æ. Karlsson
EMEthan J. Mohns
Ethan J. Mohns
GPGonzalo Viana di Prisco
Gonzalo Viana di Prisco
MBMark S. Blumberg
Mark S. Blumberg

18 November 2022 in Neuropsychopharmacology
Verified
Journal Article
Open access
PDF file
HSHildur Sóley Sveinsdóttir
Hildur Sóley Sveinsdóttir
CCChristian Christensen
Christian Christensen
HÞHaraldur Þorsteinsson
Haraldur Þorsteinsson
PLPerrine Lavalou
Perrine Lavalou
MPMatthew O. Parker
Matthew O. Parker
KKKarl Ægir Karlsson
Karl Ægir Karlsson
ADHD is a highly prevalent neurodevelopmental disorder. The first-line therapeutic for ADHD, methylphenidate, can cause serious side effects including weight loss, insomnia, and hypertension. Therefore, the development of non-stimulant-based therapeutics has been prioritized. However, many of these also cause other effects, most notably somnolence. Here, we have used a uniquely powerful genetic model and unbiased drug screen to identify novel ADHD non-stimulant therapeutics. We first found thatadgrl3.1null (adgrl3.1−/−) zebrafish larvae showed a robust hyperactive phenotype. Although the hyperactivity was rescued by three ADHD non-stimulant therapeutics, all interfered significantly with sleep. Second, we used wild-type zebrafish larvae to characterize a simple behavioral phenotype generated by atomoxetine and screened the 1200 compound Prestwick Chemical Library® for a matching behavioral profile resulting in 67 hits. These hits were re-assayed in theadgrl3.1−/−. Using the previously identified non-stimulants as a positive control, we identified four compounds that matched the effect of atomoxetine: aceclofenac, amlodipine, doxazosin, and moxonidine. We additionally demonstrated cognitive effects of moxonidine in mice using a T-maze spontaneous alternation task. Moxonidine, has high affinity for imidazoline 1 receptors. We, therefore, assayed a pure imidazoline 1 agonist, LNP599, which generated an effect closely matching other non-stimulant ADHD therapeutics suggesting a role for this receptor system in ADHD. In summary, we introduce a genetic model of ADHD in zebrafish and identify five putative therapeutics. The findings offer a novel tool for understanding the neural circuits of ADHD, suggest a novel mechanism for its etiology, and identify novel therapeutics.

1 September 2011 in Zebrafish
Verified
Journal Article
Closed access
BSBenjamín Sigurgeirsson
Benjamín Sigurgeirsson
HÞHaraldur Þorsteinsson
Haraldur Þorsteinsson
HAHrönn Arnardóttir
Hrönn Arnardóttir
IJIngibjörg Þ. Jóhannesdóttir
Ingibjörg Þ. Jóhannesdóttir
KKKarl Ægir Karlsson
Karl Ægir Karlsson
We describe, for the first time, the effects of the wakefulness-promoting drug modafinil on sleep and wakefulness in larval zebrafish. Modafinil is currently used to treat narcolepsy, hypersomnia, and shift-work disorder by increasing wakefulness. Tolerance and dependence are limited with modafinil use, differentiating it from common stimulants; however, the neural mechanisms of action of modafinil are still unknown. Zebrafish, a low-cost, prolific, and genetically tractable animal model, have recently become a key model in sleep research. Zebrafish express circadian rhythms, sleep homeostasis, and sleep pressure, and, in addition, respond to common hypnotics and stimulants in a manner similar to mammals. Therefore, in the current experiment we characterize the effects of modafinil on sleep–wake cycles in larval zebrafish as a first step to gaining further insight into the neural mechanisms underlying the effects of modafinil. We show that modafinil modulates sleep–wake activity in larval zebrafish in a manner consistent with what would be predicted from mammalian data. Modafinil increases wakefulness by lengthening wake-bouts, an effect that likely restricted to the night (lights-off). These results validate the use of zebrafish as an animal model for the study of sleep and provide a means for dissecting the neural mechanisms of modafinil, and, more broadly, sleep disorders.

18 December 2020 in Frontiers in Behavioral Neuroscience
Verified
Journal Article
Open access
PDF file
CCChristian Christensen
Christian Christensen
HÞHaraldur Þorsteinsson
Haraldur Þorsteinsson
VMValerie Helene Maier
Valerie Helene Maier
KKKarl Ægir Karlsson
Karl Ægir Karlsson
Parkinson’s disease (PD) has been modeled in several animal species using the neurotoxins 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its oxidized product 1-methyl-4-phenylpyridinium (MPP+). MPP+ selectively kills dopaminergic neurons in pars compacta of the substantia nigra, inducing parkinsonian symptoms in animals. Typically, neurotoxicity models of PD in zebrafish assess acute drug effects on locomotion. In the present study, we examined the lasting effects of MPP+ exposure and drug treatment in zebrafish larvae. Larvae were incubated in 500 μM MPP+, from 1 to 5 days post fertilization (dpf), followed by 24 h drug-free acclimation. At 6 dpf, the behavior was analyzed for locomotion, thigmotaxis, and sleep. Next, in separate assays we assessed the drug effects of brain injected glial cell-derived neurotrophic factor (GDNF) and 4-phenylbutyrate (PBA), co-incubated with MPP+. We show that MPP+ exposure consistently reduces swim distance, movement frequency, and cumulative time of movement; thus mimicking a parkinsonian phenotype of reduced movement. In contrast, MPP+ exposed larvae demonstrate reduced anxiety-like behavior and exhibit a sleep phenotype inconsistent with human PD: the larvae display longer sleep bouts, less sleep fragmentation, and more sleep. Previously reported rescuing effects of PBA were not replicated in this study. Moreover, whereas GDNF attenuated the sleep phenotype induced by MPP+, PBA augmented it. The current data suggest that MPP+ exposure generates a multifaceted phenotype in zebrafish and highlights that analyzing a narrow window of data can reveal effects that may be inconsistent with longer multi-parameter approaches. It further indicates that the model generally captures motor symptoms more faithfully than non-motor symptoms.

14 February 2025 in Neuropsychopharmacology
Verified
Journal Article
Open access
HÞHaraldur Þorsteinsson
Haraldur Þorsteinsson
HBHannes A. Baukmann
Hannes A. Baukmann
HSHildur S. Sveinsdóttir
Hildur S. Sveinsdóttir
DHDagmar Þ. Halldórsdóttir
Dagmar Þ. Halldórsdóttir
BGBartosz Grzymala
Bartosz Grzymala
KKKarl Æ. Karlsson
Karl Æ. Karlsson
ADHD is a chronic neurodevelopmental disorder that significantly affects life outcomes, and current treatments often have adverse side effects, high abuse potential, and a 25% non-response rate, highlighting the need for new therapeutics. This study investigates amlodipine, an L-type calcium channel blocker, as a potential foundation for developing a novel ADHD treatment by integrating findings from animal models and human genetic data. Amlodipine reduced hyperactivity in SHR rats and decreased both hyperactivity and impulsivity in adgrl3.1−/− zebrafish. It also crosses the blood-brain barrier, reducing telencephalic activation. Crucially, Mendelian Randomization analysis linked ADHD to genetic variations in L-type calcium channel subunits (α1-C; CACNA1C, β1; CACNB1, α2δ3; CACNA2D3) targeted by amlodipine, while polygenic risk score analysis showed symptom mitigation in individuals with high ADHD genetic liability. With its well-tolerated profile and efficacy across species, supported by genetic evidence, amlodipine shows potential to be refined and developed into a novel treatment for ADHD.

1 September 2015 in Behavioural Brain Research
Verified
Journal Article
Closed access
BÁB.B. Árnason
B.B. Árnason
HÞH. Þorsteinsson
H. Þorsteinsson
KKK.æ. Karlsson
K.æ. Karlsson